Inhibikase Therapeutics (IKT) Shares Outstanding (2020 - 2026)

Inhibikase Therapeutics (IKT) has 5 years of Shares Outstanding (Entity) data on file, last reported at $23.7 million in Q4 2024.

• On a quarterly basis, Shares Outstanding (Entity) rose 283.3% year-over-year to $23.7 million in Q4 2024; TTM through Dec 2024 was $23.7 million, a 283.3% increase from a year earlier, with the FY2024 full-year figure at $23.7 million, up 283.3% from the prior year.
• Shares Outstanding (Entity) for Q4 2024 stood at $23.7 million, up from $7.5 million in the prior quarter.
• Over the last five years, Shares Outstanding (Entity) for IKT reached as high as $23.7 million in Q4 2024 and fell as low as $1.4 million in Q1 2020.
• Historically, Shares Outstanding (Entity) has averaged $5.0 million across 5 years, with a median of $4.2 million in 2022.
• Across the five-year window, Shares Outstanding (Entity) increased 0.29% in 2022 and surged 283.3% in 2024, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $1.4 million in 2020, then soared by 121.72% to $3.0 million in 2021, then soared by 38.54% to $4.2 million in 2022, then jumped by 47.13% to $6.2 million in 2023, then jumped by 283.3% to $23.7 million in 2024.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $23.7 million in Q4 2024, $7.5 million in Q3 2024, and $7.2 million in Q2 2024.